View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Oct. 19, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	0001069530
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		46,141,935

Condensed Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

^[1]

Current assets:

Cash and cash equivalents

$ 21,214

$ 31,299

Marketable securities

550

Other current assets

456

392

Total current assets

22,220

31,691

Property and equipment, net

250

215

Other assets

Total assets

22,482

31,918

Current liabilities:

Accounts payable

1,083

1,034

Accrued development expense

744

894

Accrued compensation and benefits

340

623

Total current liabilities

2,167

2,551

Noncurrent liabilities

Total liabilities

2,167

2,551

Commitments and contingencies

Stockholders' equity:

Preferred stock

Common stock

Additional paid-in capital

163,234

159,959

Accumulated other comprehensive income

Accumulated deficit

(142,966)

(130,638)

Total stockholders' equity

20,315

29,367

Total liabilities and stockholders' equity

$ 22,482

$ 31,918

[1]	Derived from the Company's audited financial statements as of December 31, 2015, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Condensed Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 2,657	$ 2,356	$ 7,841	$ 5,480
General and administrative	884	1,330	4,573	4,188
Total operating expenses	3,541	3,686	12,414	9,668
Operating loss	(3,541)	(3,686)	(12,414)	(9,668)
Interest income	23	15	86	40
Net loss	$ (3,518)	$ (3,671)	$ (12,328)	$ (9,628)
Net loss per share, basic and diluted	$ (0.08)	$ (0.08)	$ (0.27)	$ (0.21)
Shares used in computing net loss per share, basic and diluted	45,742	45,356	45,603	45,356

Condensed Statements Of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Statements Of Comprehensive Income Loss [Abstract]
Net loss	$ (3,518)	$ (3,671)	$ (12,328)	$ (9,628)
Other comprehensive income:
Net unrealized gains on marketable securities	1		1
Comprehensive loss	$ (3,517)	$ (3,671)	$ (12,327)	$ (9,628)

Condensed Statements Of Cash Flows - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Cash flows used in operating activities:

Net loss

$ (12,328)

$ (9,628)

Adjustments to reconcile net loss to net cash used in operating activities:

Non-cash stock-based compensation

3,489

2,639

Depreciation and amortization

Non-cash net interest income

(3)

Changes in operating assets and liabilities:

Other current assets

(18)

(281)

Accounts payable

725

Accrued development expense

(150)

617

Accrued compensation and benefits

(283)

394

Net cash used in operating activities

(9,203)

(5,505)

Cash flows provided by (used in) investing activities:

Purchases of property and equipment

(76)

(195)

Purchases of marketable securities

(2,046)

(3,847)

Maturities of marketable securities

1,500

2,950

Net cash used in investing activities

(622)

(1,092)

Cash flows used in financing activities:

Cash used for statutory taxes for net exercise of Performance Awards

(214)

Deferred financing costs

(46)

Net cash used in financing activities

(260)

Net decrease in cash and cash equivalents

(10,085)

(6,597)

Cash and cash equivalents at beginning of the period

31,299

^[1]

40,590

Cash and cash equivalents at end of the period

$ 21,214

$ 33,993

[1]	Derived from the Company's audited financial statements as of December 31, 2015, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

General	9 Months Ended
General	Sep. 30, 2016
General [Abstract]
General	Note 1. General Pain Therapeutics, Inc. develops proprietary drugs that offer significant improvements to patients and healthcare professionals. We generally focus our drug development efforts on disorders of the nervous system, such as chronic pain. In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all. We have prepared the accompanying unaudited condensed financial statements of Pain Therapeutics, Inc. in accordance with generally accepted accounting principles for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2016. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2015. We have evaluated subsequent events through the date of filing this Form 10-Q.

Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Significant Accounting Policies [Abstract]

Significant Accounting Policies

Note 2. Significant Accounting Policies

Use of Estimates

We make estimates and assumptions in preparing our financial statements in conformity with accounting principles generally accepted in the United States of America. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from these estimates and assumptions.

Cash Equivalents, Marketable Securities and Concentration of Credit Risk

We invest in cash equivalents and marketable securities. We consider highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Our marketable securities include interest-bearing financial instruments, generally consisting of corporate or government securities.

We are subject to credit risk due to our investments. Our investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. We maintain our investments at one financial institution.

A change in prevailing interest rates may cause the fair value of the investment to fluctuate. We don’t recognize an impairment charge related to this type of fluctuation because the fluctuation is temporary and eliminated by the time an investment matures. We would recognize an impairment charge if and when we determine that a decline in the fair value below the amortized cost of an investment is other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.

We may elect to sell marketable securities before they mature. We hold these investments as “available for sale” and include these investments in our Balance Sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year.

Fair Value Measurements

We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs:

Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs.

Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. We use market pricing and other observable market inputs obtained from third-party providers. We use the bid price to establish fair value where a bid price is available. We base the fair value of our marketable securities on Level 2 inputs.

Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.

We include unrealized gains or losses on our investments as Accumulated other comprehensive loss in the Stockholders’ equity section of our Balance Sheets. We include changes in net unrealized gains or losses in our Statements of Comprehensive Income. We would recognize significant realized gains and losses on a specific identification basis as other income in our Statements of Operations.

Proceeds from Grants

During the first nine months of 2016, we received $1.1 million pursuant to a grant from the National Institutes of Health, or NIH, that we recorded as a reduction to our research and development expenses.

Non-cash Stock-based Compensation

We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years. For options granted to non-employees, we remeasure the fair value expense using Black-Scholes each reporting period.

We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. We multiply the number of Performance Awards by the fair market value of our common stock on the date of grant to calculate the fair value of each award. We estimate an implicit service period for achieving performance criteria for each award. We recognize the resulting fair value as expense over the implicit service period when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.

Net Loss per Share

We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options.

We include the following in the calculation of basic and diluted net loss per share (in thousands, except per share data):



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Numerator:
Net loss	$	(3,518)	$	(3,671)	$	(12,328)	$	(9,628)
Denominator:
Shares used in computing net loss per share, basic and diluted		45,742		45,356		45,603		45,356
Net loss per share, basic and diluted	$	(0.08)	$	(0.08)	$	(0.27)	$	(0.21)

Dilutive common shares excluded from net loss per share, diluted		17,024		16,939		17,957		17,466

We excluded options outstanding from the calculation of net loss per share, diluted because the effect of including options outstanding would have been anti-dilutive.

Income Taxes

We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. In 2016, we adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. The adoption of this standard had no impact on our financial statements for 2016.

We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance.

We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our Statement of Operations in that period.

We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value

9 Months Ended

Sep. 30, 2016

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value [Abstract]

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value

Note 3. Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value

Our cash, cash equivalents and marketable securities are as follows (in thousands):



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
September 30, 2016
Cash	$	403	$	—	$	—	$	403	$	—	$	403
Cash equivalents		17,062		—		—		17,062		—		17,062
Commercial paper		4,298		1		—		4,299		—		4,299
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Reported as:
Cash and cash equivalents	$	21,213		1		—	$	21,214	$	—	$	21,214
Marketable securities		550		—		—		550		—		550
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Maturities:
Matures in one year or less	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Matures one to three years		—		—		—		—		—		—
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764

December 31, 2015
Cash	$	273	$	—	$	—	$	273	$	—	$	273
Cash equivalents		22,630		—		—		22,630		—		22,630
Commercial paper		8,396		1		(1)		8,396		—		8,396
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Reported as:
Cash and cash equivalents	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Marketable securities		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Maturities:
Matures in one year or less	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Matures one to three years		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299

We did not realize any gains or losses on our investments in marketable securities in 2016 or 2015. To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.

Our assets measured at fair value on a recurring basis are as follows (in thousands):



	Level 1		Level 2		Level 3		Total
September 30, 2016
Cash and cash equivalents	$	17,465	$	—	$	—	$	17,465
Commercial paper		—		4,299		—		4,299
	$	17,465	$	4,299	$	—	$	21,764
December 31, 2015
Cash and cash equivalents	$	22,903	$	—	$	—	$	22,903
Commercial paper		—		8,396		—		8,396
	$	22,903	$	8,396	$	—	$	31,299

There were no transfers between Level 1, Level 2 and Level 3 in 2016 or 2015.

Equity And Stock-Based Compensation Expense

9 Months Ended

Sep. 30, 2016

Equity And Stock-Based Compensation Expense [Abstract]

Equity And Stock-Based Compensation Expense

Note 4. Equity and Stock-Based Compensation Expense

Stockholders’ equity activity in 2016

During 2016, our common stock outstanding and stockholders’ equity (in thousands) changed as follows:


	Common Stock	Stockholders' equity (in thousands)
Balance at December 31, 2015	45,756,117	$	29,367
Non-cash stock-related compensation for:
Stock options for employees	—		2,634
Stock options for non-employees	—		21
Performance Awards and related non-cash compensation	485,000		834
Performance Awards related to statutory taxes	(99,182)		(214)
Other comprehensive income	—		1
Net loss	—		(12,328)
Balance at September 30, 2016	46,141,935	$	20,315

In April 2016, certain employees elected to receive common stock from vested Performance Awards net of statutory taxes. This net issuance resulted in fewer shares of common stock issued and used our cash to pay these taxes on behalf of employees.

Stock option and Performance Award activity in 2016

During 2016, stock options and unvested Performance Awards outstanding under our 2008 Equity Incentive Plan changed as follows:



	Stock Options	Performance Awards
Outstanding as of December 31, 2015	18,515,254	1,889,465
Granted	355,000	150,000
Vested Performance Awards	—	(485,000)
Canceled	(1,763,097)	—
Outstanding as of September 30, 2016	17,107,157	1,554,465

The weighted average exercise price of options outstanding at September 30, 2016 was $3.60. As outstanding options vest over the current remaining vesting period of 2.4 years, we expect to recognize non-cash expense of $6.8 million. If and when outstanding Performance Awards vest, we would recognize non-cash expense of $4.7 million over the implicit service period.

Stock-based Compensation Expense in 2016

During 2016, our non-cash stock-related compensation expenses were as follows (in thousands):



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Research and development
Vesting of stock options	$	318	$	280	$	997	$	904
Vesting of Performance Awards		—		—		430		—
		318		280		1,427		904
General and administrative
Vesting of stock options		527		515		1,658		1,735
Vesting of Performance Awards		—		—		404		—
		527		515		2,062		1,735
Total non-cash stock-based compensation expenses
Vesting of stock options		845		795		2,655		2,639
Vesting of Performance Awards		—		—		834		—
	$	845	$	795	$	3,489	$	2,639

Non-cash stock-related compensation expense for vesting of Performance Awards in the nine months ended September 30, 2016 resulted from the March 2016 resubmission of the NDA for REMOXY® ER (oxycodone capsules CII).

At-the-market equity program

In December 2015 we established an at-the-market equity program for the sale of up to 10.0 million shares of our common stock. We have not yet issued any shares under the program. At September 30, 2016, we have deferred financing costs of $0.1 million paid in connection with this program.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2016
Income Taxes [Abstract]
Income Taxes	Note 5. Income Taxes We did not provide for income taxes in the third quarter or first nine months of 2016 because we have projected a net loss for the full year 2016.

Commitments

9 Months Ended

Sep. 30, 2016

Commitments [Abstract]

Commitments

Note 6. Commitments

We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations that are cancelable. Our obligations under these contracts are largely based on services performed.

We have a non-cancelable operating lease for approximately 6,000 square feet of office space in Austin, Texas that expires in December 2017. Minimum lease payments are as follows (in thousands):



	2016		2017		Total
Minimum lease payments	$	146	$	147	$	293

Legal Proceedings	9 Months Ended
Legal Proceedings	Sep. 30, 2016
Legal Proceedings [Abstract]
Legal Proceedings	Note 7. Legal Proceedings KB Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy, No. 11-cv-01034 (W.D. Tex.) On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. At a preliminary settlement conference on August 26, 2016, the Court approved a Stipulated Settlement Agreement and ordered a Final Settlement Hearing for December 16, 2016.

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Sep. 30, 2016
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements	Note 8. Recently Issued Accounting Pronouncements We reviewed recently issued accounting pronouncements and have adopted or plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Significant Accounting Policies (Policy)

9 Months Ended

Sep. 30, 2016

Significant Accounting Policies [Abstract]

Use of Estimates

Cash Equivalents, Marketable Securities and Concentration of Credit Risk

Fair Value Measurements

We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs:

Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs.

Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.

Proceeds from Grants

Non-cash Stock-based Compensation

Net Loss per Share

We include the following in the calculation of basic and diluted net loss per share (in thousands, except per share data):



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Numerator:
Net loss	$	(3,518)	$	(3,671)	$	(12,328)	$	(9,628)
Denominator:
Shares used in computing net loss per share, basic and diluted		45,742		45,356		45,603		45,356
Net loss per share, basic and diluted	$	(0.08)	$	(0.08)	$	(0.27)	$	(0.21)

Dilutive common shares excluded from net loss per share, diluted		17,024		16,939		17,957		17,466

We excluded options outstanding from the calculation of net loss per share, diluted because the effect of including options outstanding would have been anti-dilutive.

Income Taxes

We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.M)
-URI http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Significant Accounting Policies [Abstract]

Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Numerator:
Net loss	$	(3,518)	$	(3,671)	$	(12,328)	$	(9,628)
Denominator:
Shares used in computing net loss per share, basic and diluted		45,742		45,356		45,603		45,356
Net loss per share, basic and diluted	$	(0.08)	$	(0.08)	$	(0.27)	$	(0.21)

Dilutive common shares excluded from net loss per share, diluted		17,024		16,939		17,957		17,466

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value (Tables)

9 Months Ended

Sep. 30, 2016

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value [Abstract]

Cash, Cash Equivalents And Marketable Securities



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
September 30, 2016
Cash	$	403	$	—	$	—	$	403	$	—	$	403
Cash equivalents		17,062		—		—		17,062		—		17,062
Commercial paper		4,298		1		—		4,299		—		4,299
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Reported as:
Cash and cash equivalents	$	21,213		1		—	$	21,214	$	—	$	21,214
Marketable securities		550		—		—		550		—		550
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Maturities:
Matures in one year or less	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764
Matures one to three years		—		—		—		—		—		—
	$	21,763	$	1	$	—	$	21,764	$	—	$	21,764

December 31, 2015
Cash	$	273	$	—	$	—	$	273	$	—	$	273
Cash equivalents		22,630		—		—		22,630		—		22,630
Commercial paper		8,396		1		(1)		8,396		—		8,396
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Reported as:
Cash and cash equivalents	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Marketable securities		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Maturities:
Matures in one year or less	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299
Matures one to three years		—		—		—		—		—		—
	$	31,299	$	1	$	(1)	$	31,299	$	—	$	31,299

Assets Measured At Fair Value On Recurring Basis



	Level 1		Level 2		Level 3		Total
September 30, 2016
Cash and cash equivalents	$	17,465	$	—	$	—	$	17,465
Commercial paper		—		4,299		—		4,299
	$	17,465	$	4,299	$	—	$	21,764
December 31, 2015
Cash and cash equivalents	$	22,903	$	—	$	—	$	22,903
Commercial paper		—		8,396		—		8,396
	$	22,903	$	8,396	$	—	$	31,299

Equity And Stock-Based Compensation Expense (Tables)

9 Months Ended

Sep. 30, 2016

Equity And Stock-Based Compensation Expense [Abstract]

Common Stock Outstanding and Stockholders' Equity


	Common Stock	Stockholders' equity (in thousands)
Balance at December 31, 2015	45,756,117	$	29,367
Non-cash stock-related compensation for:
Stock options for employees	—		2,634
Stock options for non-employees	—		21
Performance Awards and related non-cash compensation	485,000		834
Performance Awards related to statutory taxes	(99,182)		(214)
Other comprehensive income	—		1
Net loss	—		(12,328)
Balance at September 30, 2016	46,141,935	$	20,315

Stock Option and Performance Award activity



	Stock Options	Performance Awards
Outstanding as of December 31, 2015	18,515,254	1,889,465
Granted	355,000	150,000
Vested Performance Awards	—	(485,000)
Canceled	(1,763,097)	—
Outstanding as of September 30, 2016	17,107,157	1,554,465

Summary Of Non-Cash Stock-Based Compensation



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Research and development
Vesting of stock options	$	318	$	280	$	997	$	904
Vesting of Performance Awards		—		—		430		—
		318		280		1,427		904
General and administrative
Vesting of stock options		527		515		1,658		1,735
Vesting of Performance Awards		—		—		404		—
		527		515		2,062		1,735
Total non-cash stock-based compensation expenses
Vesting of stock options		845		795		2,655		2,639
Vesting of Performance Awards		—		—		834		—
	$	845	$	795	$	3,489	$	2,639

Commitments (Tables)

9 Months Ended

Sep. 30, 2016

Commitments [Abstract]

Future Minimum Lease Payments



	2016		2017		Total
Minimum lease payments	$	146	$	147	$	293

Significant Accounting Policies (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2016 USD ($)
Significant Accounting Policies [Abstract]
Contractual maturity of a particular investment	1 year
Reduction to research and development expense	$ 1.1
Vesting period of stock options	4 years

Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net loss	$ (3,518)	$ (3,671)	$ (12,328)	$ (9,628)
Denominator:
Shares used in computing net loss per share, basic and diluted	45,742	45,356	45,603	45,356
Net loss per share, basic and diluted	$ (0.08)	$ (0.08)	$ (0.27)	$ (0.21)
Dilutive common shares excluded from net loss per share, diluted	17,024	16,939	17,957	17,466

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Transfers from level 1 to level 2	$ 0	$ 0
Transfers from level 2 to level 1	0	0
Net transfers to level 3	0	0
Marketable Securities [Member]
Gain (loss) on investments	$ 0	$ 0

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.

+ References + Details

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value (Cash, Cash Equivalents And Marketable Securities) (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Sep. 30, 2015

Dec. 31, 2014

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents

$ 21,214

$ 31,299

^[1]

$ 33,993

$ 40,590

Cash and cash equivalents, Short Term Investment, Amortized Cost

21,763

31,299

Cash and cash equivalents, Short Term Investment Unrealized Gains

Cash and cash equivalents, Short Term Investment Unrealized Losses

(1)

Accrued Interest

Estimated Fair Value, Marketable securities

550

Cash and cash equivalents, Short Term Investment, Fair Value

21,764

31,299

Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Short Term Investment, Fair Value

21,764

31,299

Marketable Securities [Member]

Schedule of Available-for-sale Securities [Line Items]

Available-for-sale securities, Amortized Cost Basis

550

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

Accrued Interest

Estimated Fair Value, Marketable securities

550

Marketable Securities [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Estimated Fair Value, Marketable securities

550

Cash [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash

403

273

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

Accrued Interest

Cash and cash equivalents, Fair Value

403

273

Cash [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Fair Value

403

273

Cash Equivalents [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash equivalents

17,062

22,630

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

Accrued Interest

Cash and cash equivalents, Fair Value

17,062

22,630

Cash Equivalents [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Fair Value

17,062

22,630

Cash And Cash Equivalents [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents

21,213

31,299

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

(1)

Accrued Interest

Cash and cash equivalents, Fair Value

21,214

31,299

Cash And Cash Equivalents [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Fair Value

21,214

31,299

Commercial Paper [Member]

Schedule of Available-for-sale Securities [Line Items]

Available-for-sale securities, Amortized Cost Basis

4,298

8,396

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

(1)

Accrued Interest

Estimated Fair Value, Marketable securities

4,299

8,396

Commercial Paper [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Estimated Fair Value, Marketable securities

4,299

8,396

Matures In One Year Or Less [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Short Term Investment, Amortized Cost

21,763

31,299

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

(1)

Accrued Interest

Cash and cash equivalents, Short Term Investment, Fair Value

21,764

31,299

Matures In One Year Or Less [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Short Term Investment, Fair Value

21,764

31,299

Matures One To Three Years [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Short Term Investment, Amortized Cost

Available-for-sale securities, Gross Unrealized Gains

Available-for-sale securities, Gross Unrealized Losses

Accrued Interest

Cash and cash equivalents, Short Term Investment, Fair Value

Matures One To Three Years [Member] | Estimated Fair Value, Fair Value Disclosure [Member]

Schedule of Available-for-sale Securities [Line Items]

Cash and cash equivalents, Short Term Investment, Fair Value

[1]	Derived from the Company's audited financial statements as of December 31, 2015, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 21,764	$ 31,299
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	17,465	22,903
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,299	8,396
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	17,465	22,903
Level 1 [Member] \| Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	17,465	22,903
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,299	8,396
Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,299	8,396
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Equity And Stock-Based Compensation Expense (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Vesting period of stock options			4 years
Non-cash stock-based compensation expense	$ 845	$ 795	$ 3,489	$ 2,639
At-The-Market Equity Program [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Offering of common stock shares					10,000,000
Common stock, shares issued	0		0
Deferred financing costs	$ 100		$ 100
Employee Stock Options [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Vesting period of stock options			2 years 4 months 24 days
Non-cash stock-based compensation expense	$ 845	$ 795	$ 2,655	$ 2,639
Employee Stock Options [Member] \| 2008 Equity Incentive Plan [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted average exercise price or options	$ 3.60		$ 3.60
Non-cash stock-based compensation expense			$ 6,800
Performance Awards [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense			834
Performance Awards [Member] \| 2008 Equity Incentive Plan [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense			$ 4,700

Equity And Stock-Based Compensation Expense (Common Stock Outstanding and Stockholders' Equity) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Common stock, balance at December 31			45,756,117
Common stock, balance at September 30	46,141,935		46,141,935
Stockholders' equity, balance at December 31			$ 29,367
Stockholders' equity, Performance Awards related to statutory taxes			(214)
Other comprehensive income	$ 1		1
Net loss	(3,518)	$ (3,671)	(12,328)	$ (9,628)
Stockholders' equity, balance at September 30	$ 20,315		20,315
Employee Stock Options [Member]
Stockholders' equity, Stock options			2,634
Non-Employee Stock Options [Member]
Stockholders' equity, Stock options			$ 21
Performance Awards [Member]
Common Stock, Performance Awards and related non-cash compensation			485,000
Common Stock, Performance Awards related to statutory taxes			(99,182)
Stockholders' equity, Performance Awards and related non-cash compensation			$ 834
Stockholders' equity, Performance Awards related to statutory taxes			$ (214)

Equity And Stock-Based Compensation Expense (Stock Option and Performance Award Activity) (Details)	9 Months Ended
	Sep. 30, 2016 shares
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2015	18,515,254
Granted	355,000
Vested Performance Awards
Canceled	(1,763,097)
Outstanding as of September 30, 2016	17,107,157
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2015	1,889,465
Granted	150,000
Vested Performance Awards	(485,000)
Cancelled
Outstanding as of September 30, 2016	1,554,465

Equity And Stock-Based Compensation Expense (Summary Of Non-Cash Stock-Based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	$ 845	$ 795	$ 3,489	$ 2,639
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	318	280	1,427	904
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	527	515	2,062	1,735
Employee Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	845	795	2,655	2,639
Employee Stock Options [Member] \| Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	318	280	997	904
Employee Stock Options [Member] \| General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense	$ 527	$ 515	1,658	$ 1,735
Performance Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense			834
Performance Awards [Member] \| Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense			430
Performance Awards [Member] \| General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Non-cash stock-based compensation expense			$ 404

Commitments (Narrative) (Details) - Austin, TX [Member]	9 Months Ended
Commitments (Narrative) (Details) - Austin, TX [Member]	Sep. 30, 2016 ft²
Operating Leased Assets [Line Items]
Office space	6,000
Operating lease expiration year	2017-12

Commitments (Future Minimum Lease Payments) (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Commitments [Abstract]
Minimum lease payments, 2016	$ 146
Minimum lease payments, 2017	147
Total	$ 293